Argenx Se (ARGX) Total Liabilities (2015 - 2026)
Argenx Se's (ARGX) quarterly Total Liabilities came in at $1.6 billion in Q2 2026, up 49.56% YoY from $1.1 billion in Q2 2025, and up 18.75% on a QoQ basis from $1.4 billion in Q4 2025.
Argenx Se (ARGX) Total Liabilities (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Total Liabilities data on file, last reported at $1.6 billion in Q2 2026.
- Quarterly Total Liabilities rose 49.56% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 49.56% YoY) and the FY2025 annual result came in at $1.4 billion, up 93.12% from the prior year.
- Total Liabilities rose to $1.6 billion in Q2 2026, from $1.4 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $1.6 billion in Q2 2026 to a low of $279.0 million in Q2 2022.
- A 5-year average of $741.5 million and a median of $534.3 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities gained 1.43% — and 2025, when it surged 102.1%.
- Tracing ARGX's Total Liabilities over 5 years: stood at $320.6 million in 2022, then jumped by 38.8% to $445.0 million in 2023, then surged by 58.27% to $704.2 million in 2024, then soared by 93.12% to $1.4 billion in 2025, then climbed by 18.75% to $1.6 billion in 2026.
- The last three Total Liabilities figures came in at $1.6 billion (Q2 2026), $1.4 billion (Q4 2025), and $1.1 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 384.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Bn |
| Dec 31, 2025 | 1.36 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Dec 31, 2024 | 704.24 Mn |
| Jun 30, 2024 | 534.31 Mn |
| Dec 31, 2023 | 444.95 Mn |
| Jun 30, 2023 | 335.74 Mn |
| Dec 31, 2022 | 320.56 Mn |
| Jun 30, 2022 | 279.02 Mn |
| Dec 31, 2021 | 316.05 Mn |
| Jun 30, 2021 | 261.09 Mn |
| Dec 31, 2020 | 586.74 Mn |
| Jun 30, 2020 | 447.19 Mn |
| Dec 31, 2019 | 423.49 Mn |
| Jun 30, 2019 | 386.25 Mn |
| Dec 31, 2018 | 45.73 Mn |
| Jun 30, 2018 | 32.29 Mn |
| Dec 31, 2017 | 30.59 Mn |
| Jun 30, 2017 | 38.74 Mn |
| Dec 31, 2016 | 45.78 Mn |